| HOME >> MEDICINE >> TECHNOLOGY |
Zometa is contraindicated in patients with hypersensitivity to zoledronic acid or other bisphosphonates, or any of the excipients in the formulation of Zometa. Hypersensitivity reactions, including rare cases of urticaria and angioedema and very rare cases of anaphylactic reaction/shock, have been reported.
Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of Zometa should not exceed 4 mg, and the duration of infusion should be no less than 15 minutes. Risk factors for the deterioration of renal function include impaired baseline renal function and multiple cycles of bisphosphonate treatment.
Zometa is not recommended in patients with bone metastases with severe renal impairment. In patients with mild to moderate renal impairment at baseline, lower doses of Zometa are recommended based on calculated creatinine clearance. Before each Zometa dose, serum creatinine should be measured and treatment should be withheld for renal deterioration until serum creatinine has returned to within 10% of the baseline value.
Zometa should not be used during pregnancy. Women of childbearing potential should be advised to avoid becoming pregnant. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
Osteonecrosis of the jaw (ONJ) has been reported predominantly in
cancer patients treated with intravenous bisphosphonates, including Zometa.
Many of these patients were also receiving chemotherapy and
corticosteroids, which may be risk factors for ONJ. Postmarketing
experience and the literature suggest a greater frequency of reports of ONJ
based on tumor type (advanced breast cancer, multiple myeloma) and dental
status (dental extraction, periodontal disease, local trauma, including
poorly fitting dentures). Many reports of ONJ involved patients with signs
of local infection, including osteomyelitis. Cancer patient
'/>"/>
| SOURCE Novartis Copyright©2008 PR Newswire. All rights reserved |